PLATFORM INTRODUCTION
Relying on its own technological iteration and innovation, as well as the upgraded proprietary platform technology, Siran Bio has established a comprehensive siRNA drug development technology platform. This platform independently encompasses the entire process of siRNA drug development, including sequence discovery, siRNA design, nucleic acid synthesis, stabilization modification, off-target modification, as well as intrahepatic delivery and dual-target platforms. These capabilities ensure high quality, efficiency, a high success rate, and a continuous output of innovative pipeline.
The company has rich experience in siRNA design, and can quickly complete the sequence design of research targets through the use of bioinformatics analysis and auxiliary design. The company has established a complete high-throughput screening platform for in vitro and in vivo test, which can complete the selection of optimal sequence targets within 3 months.
The company has developed a proprietary chemical modification platform that can significantly enhance the safety profile of siRNA while preserving its efficiency. This platform mitigates the off-target effect and improving metabolic stability, thereby ensuring the safety, efficacy, and duration of siRNA drugs.
The company has established a complete solid-phase synthesis system for nucleic acids, which can efficiently complete the synthesis, purification, and analysis of siRNA molecules, and efficiently support platform technology and pipeline research and development.
Scan to follow us
Phone：0086-512-65295956
Email：BD@canimble.com
